Becton Dickinson/$BDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Becton Dickinson
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
Ticker
$BDX
Sector
Primary listing
NYSE
Employees
74,000
Headquarters
Website
Becton Dickinson Metrics
BasicAdvanced
$54B
34.19
$5.47
0.28
$4.16
2.22%
Price and volume
Market cap
$54B
Beta
0.28
52-week high
$251.99
52-week low
$163.33
Average daily volume
1.5M
Dividend rate
$4.16
Financial strength
Current ratio
1.103
Quick ratio
0.453
Long term debt to equity
68.825
Total debt to equity
75.93
Dividend payout ratio (TTM)
74.07%
Interest coverage (TTM)
5.74%
Profitability
EBITDA (TTM)
5,919
Gross margin (TTM)
47.16%
Net profit margin (TTM)
7.41%
Operating margin (TTM)
16.44%
Effective tax rate (TTM)
15.92%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
3.96%
Return on equity (TTM)
6.17%
Valuation
Price to earnings (TTM)
34.192
Price to revenue (TTM)
2.522
Price to book
2.1
Price to tangible book (TTM)
-4.91
Price to free cash flow (TTM)
21.154
Free cash flow yield (TTM)
4.73%
Free cash flow per share (TTM)
8.842
Dividend yield (TTM)
2.22%
Forward dividend yield
2.22%
Growth
Revenue change (TTM)
7.86%
Earnings per share change (TTM)
12.91%
3-year revenue growth (CAGR)
4.10%
10-year revenue growth (CAGR)
8.56%
3-year earnings per share growth (CAGR)
-1.80%
10-year earnings per share growth (CAGR)
3.12%
3-year dividend per share growth (CAGR)
5.77%
10-year dividend per share growth (CAGR)
5.67%
What the Analysts think about Becton Dickinson
Analyst ratings (Buy, Hold, Sell) for Becton Dickinson stock.
Bulls say / Bears say
After reporting Q3 2025 adjusted EPS of $3.68—beating estimates by $0.28—and revenue of $5.51 billion, BD raised its full-year adjusted EPS guidance to $14.30–$14.45, up from $14.06–$14.34, citing strong demand for its drug-delivery devices (Reuters).
BD agreed to a $17.5 billion Reverse Morris Trust transaction to merge its Biosciences & Diagnostic Solutions division with Waters Corporation, a move projected to double Waters’ total addressable market to $40 billion and unlock $345 million in annual cost savings by 2030 (Reuters).
The company plans to invest $2.5 billion in U.S. manufacturing capacity over the next five years, strengthening its domestic production footprint and enhancing resilience of its supply chain (Reuters).
Becton Dickinson lowered its full-year adjusted EPS forecast to $14.06–$14.34, reflecting a ~$0.25 per share headwind from proposed U.S. tariffs, which sent its shares down about 5% in pre-market trading on May 1, 2025 (Reuters).
Global cuts in research funding, notably U.S. government grants, have depressed sales of BD’s research instruments, triggering a more than 15% one-day stock plunge—the worst since 1999—when the company disclosed these headwinds on May 1, 2025 (MarketWatch).
Second-quarter 2025 revenues of $5.27 billion missed the Wall Street estimate of $5.35 billion, reflecting softer top-line momentum and contributing to a 5% share decline on May 1, 2025 (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Becton Dickinson Financial Performance
Revenues and expenses
Becton Dickinson Earnings Performance
Company profitability
Becton Dickinson News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Becton Dickinson stock?
Becton Dickinson (BDX) has a market cap of $54B as of October 29, 2025.
What is the P/E ratio for Becton Dickinson stock?
The price to earnings (P/E) ratio for Becton Dickinson (BDX) stock is 34.19 as of October 29, 2025.
Does Becton Dickinson stock pay dividends?
Yes, the Becton Dickinson (BDX) stock pays dividends to shareholders. As of October 29, 2025, the dividend rate is $4.16 and the yield is 2.22%. Becton Dickinson has a payout ratio of 74.07% on a trailing twelve-month basis.
When is the next Becton Dickinson dividend payment date?
The next Becton Dickinson (BDX) dividend payment date is unconfirmed.
What is the beta indicator for Becton Dickinson?
Becton Dickinson (BDX) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.